Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The aim of this study is to evaluate the safety and efficacy of autologous adipose-derived mesenchymal cells for treating confirmed or suspected patients with SARS-CoV-2 and compromised respiratory function requiring hospitalization. The hypothesis of the Study is autologous adipose-derived mesenchymal cells given IV to eligible patients will improve clinical outcomes of COVID 19 positive patients with severe pneumonia or ARDS by reducing or avoiding cytokine storm.
Description: Incidence of unexpected adverse events within 28 days following IV administration of MSCs.
Measure: Safety - Incidence of unexpected adverse events Time: up to 28 daysDescription: Changes in progression or rate of subjects progressing to mechanical ventilation
Measure: Efficacy - Frequency of progression to mechanical ventilation Time: up to 28 daysDescription: Changes in time subjects remain on mechanical ventilation
Measure: Efficacy - Changes in length of mechanical ventilation Time: up to 28 daysDescription: Changes in length of time subjects wean off of mechanical ventilation
Measure: Efficacy - Changes in length of weaning of mechanical ventilation Time: up to 28 daysDescription: Length of Hospital Stay
Measure: Efficacy - Changes in length of hospital stay Time: up to 28 daysDescription: Mortality rate from all causes
Measure: Efficacy - Changes in mortality rate Time: up to 28 days